GlassScriptPhysician profile
Dona E Cooper-Dockery
NPI 1003093147
$1,660.46
in general payments reported to CMS, 2019-2025
20 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $58.66 · 2021: $187 · 2022: $150 · 2023: $420 · 2024: $237 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.19 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $456.44 | 2021-2025 | Vraylar, Ubrelvy, Viberzi |
| Pfizer INC. | $205.56 | 2021-2025 | |
| Novo Nordisk INC | $201.42 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bard Peripheral Vascular, INC. | $133.83 | 2019 | |
| Adc Therapeutics America, INC. | $121.36 | 2025 | |
| Allergan, INC. | $94.20 | 2019-2020 | |
| Astellas Pharma US INC | $94.00 | 2023 | |
| Abbott Laboratories | $57.61 | 2021-2022 | |
| Dexcom, INC. | $55.58 | 2024-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $30.82 | 2025 | Uzedy |
| Phadia US INC. | $28.08 | 2024 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.06 | 2024 | Jardiance |
| Amgen INC. | $24.65 | 2023 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $22.44 | 2022 | |
| Phathom Pharmaceuticals, INC. | $21.88 | 2025 | Voquezna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $20.81 | 2023 | Xarelto |
| Lilly USA, LLC | $18.91 | 2025 | Zepbound, Mounjaro |
| Acclarent, INC | $17.44 | 2021 | |
| Sumitomo Pharma America, INC. | $14.74 | 2024 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $13.63 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dona Cooper-Dockery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.